Background: Corneal xenotransplantation is an effective solution for the shortage of
an initial dose of 2 mg/kg/d, tapered over 5 weeks, and discontinued at a final dose of 0.25 mg/kg. 17 
Intravenous immunoglobulin G (IVIG)
and anti-CD 40 Ab were administered 6 months after transplantation.
IVIG (1 g/kg) was slowly administered on day 0 and 2 weeks posttransplantation. A mouse-rhesus chimeric monoclonal anti-CD40
(2C10R4, NIH Non-human Primate Reagent Resource) previously described, 18 was administered intravenously at a dose of 50-30 mg/ kg/d on day -1, day 1, post-operative day (POD) 4, POD 7, POD 10, and POD 14, once weekly until week 4, every 2 weeks until week 12, and then every 4 weeks until week 24 (15 times in total, 50 mg/kg/d in first 8 times and 30 mg/kg/d in the remaining 7 times), similar to the time schedules reported previously. 19 
| Post-operative clinical evaluations
Grafts were evaluated by slit-lamp biomicroscopy, particularly for graft clarity, edema, and neovascularization. Rejection score was graded as described previously on international consensus. 20 Graft rejection in NHPs was defined based on the sum of grades for opacity, edema, and vascularization. Graft scores exceeding 6 was considered rejection. During the follow-up period, loosened, exposed, or new vessel-inducing sutures were selectively removed. Central corneal thickness (CCT) and intraocular pressure (IOP) were measured using an ultrasonic pachymeter (Quantel Medical, Clermont-Ferrand, France) and a Tono-Pen (Medtronic Solan, Jacksonville, FL, USA), respectively. The results are the mean values of five measurements.
For visualization of living endothelial cells, enucleated eyeballs from the sacrificed recipients were evaluated using a SP-3000 specular microscope (Topcon Medical Laser Systems, Inc., Santa Clara, CA, USA).
The changes in endothelial cell density were compared between before and 6 months after transplantation in subjects in which data of endothelial cell density of donor were available before transplantation (n=3).
| Immunohistochemistry of xenografts
Corneas from sacrificed recipients were divided into two equal parts, and each portion of the cornea was subjected to hematoxylin and eosin (H&E) staining, immunohistochemical and immunofluorescent staining as described previously. 19 Immunohistochemical staining of the grafts was performed using anti-CD68 Abs (Thermo Scientific, Runcorn, UK; were evaluated using flow cytometry analysis of whole blood and draining lymph nodes as previously mentioned. 19 Data were acquired using a FACSCanto flow cytometer (Becton-Dickinson, Mountain View, CA, USA), and data analysis was carried out using FlowJo software (Tree Star, Ashland, OR). The changes in memory T cell expansion of the blood over time in anti-CD40 Ab-treated primates (n=5) were compared with those in anti-CD154 Ab-treated primates (n=4) with porcine corneal grafts, which survived successfully as previous described (as a reference) to confirm whether the T cell responses are effectively controlled in tolerable range. 17, 19 In addition, mean percentages and the numbers of effector or central memory T cells in draining lymph nodes were compared between anti-CD40 Abs-treated primates (n=4) and rejected controls (n=2, Table 1 ) that were given topical and systemic steroid after keratoplasty, using a previous study as the reference.
| Memory T cell assay
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The lymph nodes of anti-CD40-treated primates were collected after 6 months, and those of the rejected controls in which lymph nodes had been available were collected after 1 month on sacrifice.
| Anti-αGal and anti-non-αGal antibodies assay
Plasma levels of anti-αGal IgG and IgM Abs were measured using ELISA as described previously. 22, 23 In brief, mean absorbance of antiαGal Abs was expressed as artificial units (AU)/mL, and was compared with that of a calibrator. As a calibrator, serial dilutions of plasma from selected rhesus monkey were designated as 2809 AU/mL of anti-αGal IgG and 5610 AU/mL of anti-αGal IgM. Anti-αGal Ig G Abor anti-non-αGal Ig G Ab-binding responses were assessed by flow cytometry using a GTKO porcine endothelial cell lines (PEC69), and for supplemental purposes, WT porcine endothelial cells (MPN) incubated with 1/10 diluted plasma samples. 22 The level of Ab binding was determined as the net mean fluorescence intensity (nMFI 
| Donor pig-specific antibodies assay
Plasma concentrations of donor pig-specific IgM/IgG Abs were determined by the flow cross-match technique as described previ- The plasma concentration or MFI were measured every 2 weeks up to 4 months, and thereafter every 1 month until sacrifice. Mean MFI levels of donor-specific IgG and IgM Abs at 6 months were compared with those prior to treatment (n=4).
| Complement assay in aqueous humor
Concentration of C3a in the aqueous humor was evaluated using commercial ELISA kits (BD OptEIA ™ Human C3a ELISA Kit; BD Biosciences, San Diego, CA) according to the manufacturer's protocols prior to transplantation and 1, 3, and 6 months after transplantation.
The changes of complement in anti-CD40 Abs-treated primates (n=5) at 1 month were compared with those in controls with rejected grafts (n=4, Table 1 ) that were given the topical and systemic steroid in previous study 19 or topical and systemic steroid combined with tacrolimus and IVIG after keratoplasty as a reference. The changes of complement in anti-CD40 Ab-treated primates at 6 month were also compared with those prior to surgery (n=4).
| Statistical analyses
GraphPad Software (GraphPad Prism, Inc., La Jolla, CA, USA) was 
| RESULTS
| Clinical outcomes
All recipients had transparent xenocorneal grafts longer than 6 months after the transplantation except one that died due to anesthetic accident at 2 months (A clear graft was evident until death). In addition, two recipients (anti-CD40 1 and anti-CD40 2) showed successful survival longer than a year without any signs of rejection ( Figure 1 ). No corneal neovascularization was observed in all primates.
The MST of the anti-CD40 Ab group ([n=5]; >389, >382, >236, >201, and >61 days; Table 1 ) could not to be defined because all xenocorneal grafts of five recipients had survived throughout the whole study. The international guideline for a clinical trial of xenocorneal transplantation demands at least 6-months survival of five in a consecutive eight NHPs to prove an efficacy as a pre-clinical data. 20 For the welfare and animal-rights of NHPs, we tried to use minimal quantity of NHPs as possible as we could. Unfortunately, a primate had been dead during the anesthetic recovery at 2 months because the neck was accidentally flexed. However, we did not use additional NHPs, because in five consecutive NHPs, we did not experience any rejection at all. Although the graft had been still survived after 6 months in remaining NHPs, we had to sacrifice them due to limitation of the funding. The CCT was well Anterior segment optical coherence tomographic images of the enucleated eyes showed a well-adapted donor-recipient junction, and topography showed tolerable range of the refractive diopter and astigmatism (Fig. S1 ).
Neither ocular nor systemic adverse events including side effects of anti-CD40 Ab or CMV infection due to long-term immunosuppressive therapy were observed in any recipients (Figs. S2 and S3).
| Cellular infiltration into the grafted porcine cornea
In H&E stains, all recipients with anti-CD40 Abs treatment showed Figure 2A and Figure 3A ; upper panel), while infiltration of those cells was 
| Plasma donor pig-specific antibody assay and IgG deposition in porcine corneal grafts
The level of anti-donor-specific Ig M and Ig G Ab were not changed throughout the follow-up period ( Figure 4A , B, and E) and the differences were not statistically significant between the baseline and 6 month post-operative time point (P>.05, Wilcoxon signed rank test).
Transient peak of Ig G Abs in early post-operative period may be caused by non-specific bindings of previously existing antibodies in IVIG (Fig. S4 A) . Immunofluorescent staining showed that IgG deposits were barely observed in the graft with anti-CD40 Ab treatment ( Figure 4C ), while deposits were densely found in the rejected graft in the positive control ( Figure 4D ).
| Plasma anti-Gal antibody assay and αGal expression in porcine corneal grafts
The level of anti-αGal IgM Ab was not increased throughout the study period ( Figure 5A 
| Aqueous complement C3a assay and complement C3c deposition in porcine corneal grafts
There was no clinically relevant increase in C3a concentration in aqueous humor at 6 months compared with that of baseline level (Figure 6A , E; P>.05, Wilcoxon signed rank test). At 4 weeks after transplantation, the mean aqueous C3a concentration was significantly lower in anti-CD40 Abs-treated primates than that in rejected controls (P=.0159, Mann-Whitney U test; Figure 6B ). The grafts of the anti-CD40 Ab-treated primates did not show a deposition of C3c in the graft ( Figure 6C ), while rejected graft of the control showed pronounced deposition of C3c in the graft ( Figure 6D ).
| Memory T cell changes in whole blood and draining lymph nodes
The level of interferon-gamma (IFNγ) secreting CD4 + and CD8 IgG reactivity against non-donor third-party PBMCs using plasma from the primates given anti-CD40 Abs and IVIG (n=5), a similar spike was observed in early post-operative period (Fig. S4 A) . The increased Ig G binding against porcine PBMCs was also observed when mixed with plasma of a naïve primate in vitro after the addition of IV IG (Fig. S4 B) .
Plasma levels of anti-αGal IgG Abs in a naïve primate or a human were This anti-CD40 Ab-mediated inhibition works well in vitro and as corroborated by our in vivo models. 30 In our study, high dosage of anti-CD40 (50 mg/kg) was initially administered for eight times, and subsequently it was switched to low dosage administration (30 mg/kg) for seven times during 6 months, which worked efficiently. Although human and rhesus CD40 share 95% homology of amino acid molecules, an in vitro study revealed lower inhibitory action of anti-CD40
Ab (clone of 2C10R4) against proliferation of human PBMCs compared with that against the proliferation of rhesus PBMCs. 30 Therefore, adjustment of the administration may be required in human clinical trials 12.7%, 15.4%, 6.4%, 9.9%, and 6.5%); however, they recovered the weight back to normal after 2 weeks of transplantation.
Notably, we found no expression of αGal in surviving graft; by contrast, abundant expression of αGal was found in rejected grafts which corresponds with our previous studies. 
